Summit Creek Advisors LLC Has $13.98 Million Position in LeMaitre Vascular, Inc. $LMAT

Summit Creek Advisors LLC decreased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 168,384 shares of the medical instruments supplier’s stock after selling 7,308 shares during the quarter. LeMaitre Vascular makes up about 1.9% of Summit Creek Advisors LLC’s holdings, making the stock its 27th biggest position. Summit Creek Advisors LLC owned approximately 0.75% of LeMaitre Vascular worth $13,984,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Annex Advisory Services LLC lifted its holdings in shares of LeMaitre Vascular by 535.2% during the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock valued at $18,243,000 after buying an additional 185,085 shares during the last quarter. Millennium Management LLC increased its stake in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Invesco Ltd. raised its holdings in shares of LeMaitre Vascular by 34.5% during the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock valued at $19,753,000 after purchasing an additional 60,438 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of LeMaitre Vascular in the first quarter worth about $4,631,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Bridget A. Ross sold 2,500 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. The trade was a 37.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 20,815 shares of company stock valued at $1,929,206 over the last ninety days. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Trading Down 1.1%

Shares of LMAT stock opened at $86.27 on Thursday. The firm has a market capitalization of $1.95 billion, a P/E ratio of 41.88, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The firm’s fifty day simple moving average is $89.94 and its 200 day simple moving average is $87.01. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the prior year, the firm earned $0.52 EPS. The business’s revenue was up 15.0% on a year-over-year basis. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several analyst reports. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Barrington Research reiterated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Finally, Roth Capital reissued a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a research report on Wednesday. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $100.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.